Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 5/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15349917 | 0.87 | DYRK1A (0.65) | DYRK1AALDH1A1TDP1CYP3A4MAPT | |
| SCHEMBL1040735 | 0.86 | DYRK1A (0.63) | DYRK1AALDH1A1TDP1CYP3A4MAPT | |
| SCHEMBL1038566 | 0.86 | TDP1 (0.62) | DYRK1AALDH1A1TDP1CYP3A4MAPT | |
| SCHEMBL1041605 | 0.83 | DYRK1A (0.57) | DYRK1AALDH1A1TDP1CYP3A4MAPT | |
| SCHEMBL8401384 | 0.83 | MEN1 (0.55) | DYRK1AALDH1A1TDP1CYP3A4MAPT | |
| SCHEMBL2762212 | 0.82 | MEN1 (0.61) | DYRK1AALDH1A1TDP1CYP3A4MAPT | |
| SCHEMBL15349556 | 0.82 | DYRK1A (0.56) | DYRK1AALDH1A1TDP1CYP3A4MAPT | |
| SCHEMBL2212181 | 0.80 | ALDH1A1 (0.54) | ALDH1A1TDP1CYP3A4MAPTMEN1 | |
| SCHEMBL9620871 | 0.80 | DYRK1A (0.53) | DYRK1AALDH1A1TDP1CYP3A4MAPT | |
| SCHEMBL20660046 | 0.79 | DYRK1A (0.80) | DYRK1AALDH1A1TDP1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12377083-B2 | Lysophosphatidic acid receptor antagonist and preparation method therefor | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2025-08-05 | — | — | US | disclosed |
| CN-112771027-B | Lysophosphatidic acid receptor antagonists and process for preparing the same | 武汉朗来科技发展有限公司 | 2024-03-05 | — | — | CN | disclosed |
| US-20220079928-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2022-03-17 | — | — | US | disclosed |
| EP-3912975-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND PREPARATION METHOD THEREFOR | Wuhan LL Science And Technology Development Co., Ltd. (CN) | 2021-11-24 | — | — | EP | disclosed |
| WO-2020147739-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND PREPARATION METHOD THEREFOR | 武汉朗来科技发展有限公司 | 2020-07-23 | — | — | WO | disclosed |
| EP-2270006-A1 | Pyridazine derivatives useful as vanilloid receptor ligands | Amgen, Inc (US) | 2011-01-05 | — | — | EP | disclosed |
| US-7332511-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7148221-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-7144888-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1717220-A2 | Vanilloid receptor ligands and their use in treatments | Amgen, Inc (US) | 2006-11-02 | — | — | EP | disclosed |
| EP-1688408-A2 | Vanilloid receptor ligands and their use in treatments | Amgen, Inc (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20050277631-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-15 | — | — | US | disclosed |
| US-20050272777-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-08 | — | — | US | disclosed |
| EP-1546116-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040082780-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2004014871-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272777-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | DYRK1A 1468/4885ALDH1A1 3253/4885TDP1 2163/4885 |
| US-12377083-B2 | Lysophosphatidic acid receptor antagonist and preparation method therefor | LPAR1, LPAR2, LPAR4 | DYRK1A 2238/4885ALDH1A1 2782/4885TDP1 4192/4885 |
| US-20220079928-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR | LPAR1, LPAR2, LPAR4 | DYRK1A 2238/4885ALDH1A1 2782/4885TDP1 4192/4885 |
| US-20050277631-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | DYRK1A 1468/4885ALDH1A1 3253/4885TDP1 2163/4885 |
| US-20040082780-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | DYRK1A 1445/4885ALDH1A1 3103/4885TDP1 2040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.